HK Stock Market Move | LEADS BIOLABS-B (09887) surged over 10% in the afternoon, and the summary of Wealthy Trust WCLC has been published, securing a global license for three antibodies with a $10 million deal.

LEADS BIOLABS-B (09887) rose over 10% in afternoon trading, and as of the time of publication, it has increased by 9.16% to HKD 76.9, with a transaction volume of HKD 213 million. On the news front, VISION BIOTECH announced that the full abstract of its self-developed PD-L1/4-1BB bispecific antibody, VILISEN (LBL-024), in combination with chemotherapy as first-line treatment for non-small cell lung cancer (NSCLC), has been officially published on the World Conference on Lung Cancer (WCLC) website. Data analysis based on the cutoff date of March 6, 2026, shows that VILISEN combined with chemotherapy demonstrates encouraging objective response rates (ORR) in the overall population, with strong tumor shrinkage effects observed in both squamous and non-squamous subgroups. Notably, the data published in this abstract has a follow-up time of only 3.6 months, and the latest data with a follow-up time exceeding 7 months will be presented at a verbal report during the conference on September 14. It is worth mentioning that VISION BIOTECH announced that its subsidiary, Leads US, has received written notice from its partner Aditum Bio's Oblenio Bio, officially exercising its option to retain global development and commercialization rights for the BCMA/CD19/CD3 trispecific T cell engager LBL-051 under the agreement signed in November 2024. Oblenio Bio will pay VISION BIOTECH a non-refundable fee of USD 10 million in a lump sum.